Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis

dc.creatorRomiti, R.
dc.creatorValenzuela F., Manuel A.
dc.creatorChouela, E. N.
dc.creatorXu, W.
dc.creatorPangallo, B.
dc.creatorMoriarty, S. R.
dc.creatorGürbüz, S.
dc.creatorRiedl, E.
dc.date.accessioned2019-10-15T12:23:50Z
dc.date.available2019-10-15T12:23:50Z
dc.date.created2019-10-15T12:23:50Z
dc.date.issued2019
dc.identifierBritish Journal of Dermatology, Volumen 181, Issue 1, 2019, Pages 202-203
dc.identifier13652133
dc.identifier00070963
dc.identifier10.1111/bjd.17604
dc.identifierhttps://repositorio.uchile.cl/handle/2250/171626
dc.languageen
dc.publisherBlackwell Publishing Ltd
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile
dc.sourceBritish Journal of Dermatology
dc.subjectDermatology
dc.titlePrevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis
dc.typeArtículo de revista


Este ítem pertenece a la siguiente institución